New drug trial aims to halt rapid nerve damage in GBS
Disease control
Recruiting now
This study is testing a single dose of an investigational drug called tanruprubart (ANX005) in people recently diagnosed with Guillain-Barré syndrome (GBS). The main goals are to see how the drug behaves in the body, if it is safe, and to look for early signs that it might help c…
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC